Trials / Completed
CompletedNCT01764204
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Intensive Hospital-based Adverse Drug Reaction Monitoring Study On Patients Treated By Qingkailing Injection In The Next Two Years
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30,840 (actual)
- Sponsor
- China Academy of Chinese Medical Sciences · Academic / Other
- Sex
- All
- Age
- 1 Year – 80 Years
- Healthy volunteers
- Not accepted
Summary
To highlight the incidence of adverse reactions of Qingkailing Injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Qingkailing Injection | Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2017-12-01
- Completion
- 2018-01-01
- First posted
- 2013-01-09
- Last updated
- 2018-02-19
Locations
48 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01764204. Inclusion in this directory is not an endorsement.